Catalyst Biosciences (NASDAQ:CBIO) posted its earnings results on Thursday. The biopharmaceutical company reported ($1.15) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.01, Bloomberg Earnings reports.
Shares of Catalyst Biosciences stock traded down $0.62 on Friday, hitting $8.12. The stock had a trading volume of 117,448 shares, compared to its average volume of 278,614. Catalyst Biosciences has a twelve month low of $6.20 and a twelve month high of $11.44. The company has a 50 day moving average price of $8.00. The company has a current ratio of 24.94, a quick ratio of 24.94 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $97.28 million, a PE ratio of -3.03 and a beta of 2.10.
Several equities analysts have recently commented on the company. Zacks Investment Research raised Catalyst Biosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, July 2nd. ValuEngine raised Catalyst Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Catalyst Biosciences currently has a consensus rating of “Buy” and a consensus target price of $23.75.
Catalyst Biosciences Company Profile
Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.
Featured Article: Price to Earnings Ratio (PE)
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.